News
CRDL
1.360
+0.74%
0.010
Analysts Offer Insights on Healthcare Companies: Cardiol Therapeutics (CRDL) and BridgeBio Pharma (BBIO)
TipRanks · 1d ago
Cardiol Therapeutics Reports Higher Q1 2026 Loss but Stronger Cash Position
TipRanks · 2d ago
Weekly Report: what happened at CRDL last week (0504-0508)?
Weekly Report · 2d ago
Cardiol Therapeutics’ Phase II MAvERIC Pericarditis Data Accepted by JAHA as Phase III Trial Nears Completion
TipRanks · 6d ago
Cardiol Therapeutics says Phase II CardiolRx recurrent pericarditis results set for JAHA publication
PUBT · 6d ago
Stocks in play: Cardiol Therapeutics Inc.
Barchart · 6d ago
Analysts Offer Insights on Healthcare Companies: Surgery Partners (SGRY), Cardiol Therapeutics (CRDL) and Vertex Pharmaceuticals (VRTX)
TipRanks · 05/05 13:10
Weekly Report: what happened at CRDL last week (0427-0501)?
Weekly Report · 05/04 10:10
First Berlin reiterates Buy on Cardiol Therapeutics, sets USD 7.5 target price
PUBT · 04/30 11:14
Cardiol Therapeutics expands U.S. MAVERIC Phase III trial network
TipRanks · 04/28 12:12
Cardiol Therapeutics Expands U.S. Phase III MAVERIC Trial Network as Enrollment Reaches 75%
TipRanks · 04/28 12:08
Cardiol expands US MAVERIC Phase III recurrent pericarditis trial network to 25 sites
PUBT · 04/28 11:29
CARDIOL THERAPEUTICS EXPANDS U.S. MAVERIC PHASE III TRIAL NETWORK TO ADDRESS GROWING INTEREST IN THE PIVOTAL PROGRAM
Reuters · 04/28 11:27
CARDIOL THERAPEUTICS INC - MAVERIC TRIAL TARGET RECRUITMENT ANTICIPATED BY END OF Q2 2026, MAY EXTEND INTO Q3
Reuters · 04/28 11:27
Stocks in play: Cardiol Therapeutics Inc.
Barchart · 04/28 09:14
Weekly Report: what happened at CRDL last week (0420-0424)?
Weekly Report · 04/27 10:12
Weekly Report: what happened at CRDL last week (0413-0417)?
Weekly Report · 04/20 10:08
First Berlin reiterates Buy on Cardiol Therapeutics, cuts price target to USD 7.5
PUBT · 04/17 13:31
Cardiol Therapeutics Showcases MAVERIC Phase III Trial and ARCHER Results in Barchart Live Interview
TipRanks · 04/14 11:58
Cardiol CEO Elsley discusses MAVERIC Phase III trial in live X interview with Barchart
PUBT · 04/14 11:30
More
Webull provides a variety of real-time CRDL stock news. You can receive the latest news about Cardiol Therapeu through multiple platforms. This information may help you make smarter investment decisions.
About CRDL
Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.